Patents by Inventor Yasuto Akiyama
Yasuto Akiyama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220389517Abstract: An object of the present invention is to provide a method for predicting a risk of developing cancer. DNA samples were prepared from blood and cancer tissues of 2480 cancer patients and analyzed for the nucleotide sequences of exon regions using NGS. As a result, among the cancer patients, 7 patients were confirmed to have D49H mutation or A159D mutation which is a germ cell mutation.Type: ApplicationFiled: July 26, 2022Publication date: December 8, 2022Inventors: Ken YAMAGUCHI, Masatoshi KUSUHARA, Masakuni SERIZAWA, Tohru MOCHIZUKI, Keiichi OHSHIMA, Keiichi HATAKEYAMA, Kenichi URAKAMI, Shumpei OHNAMI, Yasuto AKIYAMA, Kouji MARUYAMA, Kengo INOUE, Yuji SHIMODA, Takeshi NAGASHIMA, Yoshinobu ISHIKAWA
-
Patent number: 11433141Abstract: An object is to produce a new anti-B7-H4 antibody having high specificity and affinity and provide a composition for treating cancer making use thereof. A monoclonal antibody that specifically binds to an extracellular domain protein of a human B7-H4 protein is newly produced and an “anti-B7-H4 antibody-effector cell complex” in which the monoclonal antibody and an effector cell are bound in order to enhance the antibody-dependent cellular cytotoxicity of the monoclonal antibody or a bispecific antibody comprising an antigen recognition region of the monoclonal antibody and an effector cell antigen recognition region is further produced and used as a composition for treating cancer.Type: GrantFiled: July 25, 2017Date of Patent: September 6, 2022Assignee: SHIZUOKA PREFECTUREInventors: Yasuto Akiyama, Akira Iizuka
-
Publication number: 20200255901Abstract: An object of the present invention is to provide a method for predicting a risk of developing cancer. DNA samples were prepared from blood and cancer tissues of 2480 cancer patients and analyzed for the nucleotide sequences of exon regions using NGS. As a result, among the cancer patients, 7 patients were confirmed to have D49H mutation or A159D mutation which is a germ cell mutation.Type: ApplicationFiled: August 3, 2017Publication date: August 13, 2020Inventors: Ken YAMAGUCHI, Masatoshi KUSUHARA, Masakuni SERIZAWA, Tohru MOCHIZUKI, Keiichi OHSHIMA, Keiichi HATAKEYAMA, Kenichi URAKAMI, Shumpei OHNAMI, Yasuto AKIYAMA, Kouji MARUYAMA, Kengo INOUE, Yuji SHIMODA, Takeshi NAGASHIMA, Yoshinobu ISHIKAWA
-
Publication number: 20190343964Abstract: An object is to produce a new anti-B7-H4 antibody having high specificity and affinity and provide a composition for treating cancer making use thereof. A monoclonal antibody that specifically binds to an extracellular domain protein of a human B7-H4 protein is newly produced and an “anti-B7-H4 antibody-effector cell complex” in which the monoclonal antibody and an effector cell are bound in order to enhance the antibody-dependent cellular cytotoxicity of the monoclonal antibody or a bispecific antibody comprising an antigen recognition region of the monoclonal antibody and an effector cell antigen recognition region is further produced and used as a composition for treating cancer.Type: ApplicationFiled: July 25, 2017Publication date: November 14, 2019Applicant: Shizuoka PerfectureInventors: Yasuto AKIYAMA, Akira IIZUKA
-
Patent number: 10344093Abstract: It is an object of the present invention to provide signal sequence information capable of secreting an antibody to the outside of cells in generation of the antibody by microorganisms of genus Bifidobacterium, and an antibody expression vector capable of secreting an antibody to the outside of cells by utilizing the signal sequence information. As a means for achieving the aforementioned object, there is prepared Bifidobacterium longum, which is transformed with a vector having inserted thereinto a DNA insert comprising the 5?-terminus of an antibody gene linked to the 3?-terminus of a DNA encoding a signal peptide-linker conjugate having a linker linked to the C-terminus of a signal peptide consisting of an amino acid sequence shown in SEQ ID NO: 1.Type: GrantFiled: April 17, 2015Date of Patent: July 9, 2019Assignee: Shinshu UniversityInventors: Shun-ichiro Taniguchi, Yasuto Akiyama, Takeshi Masaki, Hitomi Shimizu
-
Publication number: 20170218072Abstract: It is an object of the present invention to provide signal sequence information capable of secreting an antibody to the outside of cells in generation of the antibody by microorganisms of genus Bifidobacterium, and an antibody expression vector capable of secreting an antibody to the outside of cells by utilizing the signal sequence information. As a means for achieving the aforementioned object, there is prepared Bifidobacterium longum, which is transformed with a vector having inserted thereinto a DNA insert comprising the 5?-terminus of an antibody gene linked to the 3?-terminus of a DNA encoding a signal peptide-linker conjugate having a linker linked to the C-terminus of a signal peptide consisting of an amino acid sequence shown in SEQ ID NO: 1.Type: ApplicationFiled: April 17, 2015Publication date: August 3, 2017Inventors: Shun-ichiro Taniguchi, Yasuto Akiyama, Takeshi Masaki, Hitomi Shimizu
-
Patent number: 8796320Abstract: Provided is a 1,3,4-oxadiazole-2-carboxamide compound which has STAT3 inhibitory activity and is useful as an anticancer agent. Provided is a 1,3,4-oxadiazole-2-carboxamide compound represented by formula (I) or a pharmacologically acceptable salt thereof (in the formula, Ar represents a furyl group or the like; R1 represents a hydrogen atom or the like; and —X—Y represents a diaryl group such as a biphenyl group).Type: GrantFiled: December 28, 2010Date of Patent: August 5, 2014Assignees: General Incorporated Association Pharma Valley Project Supporting Organization, Pharma Design, Shizuoka Prefecture, Kumamoto Health Science University, Kabushiki Kaisha Yakult HonshaInventors: Akira Asai, Kenji Matsuno, Naohisa Ogo, Osamu Takahashi, Yoshiaki Masuda, Ayumu Muroya, Yasuto Akiyama, Tadashi Ashizawa, Tadashi Okawara
-
Publication number: 20140030296Abstract: A method for enhancing a vaccine therapy effect by a vaccine composition. The method including a step of implanting ?-tricalcium phosphate in an inside of a body of a subject, and a step of administering the vaccine composition to the subject at the same time with or before or after the implanting step.Type: ApplicationFiled: July 23, 2013Publication date: January 30, 2014Applicants: SHIZUOKA PREFECTURE, OLYMPUS CORPORATIONInventors: Kouji MARUYAMA, Mitsuru TAKAHASHI, Masahiro NAKAGAWA, Yasuto AKIYAMA, Hidee ISHII, Jinyan CHENG
-
Patent number: 8466290Abstract: The present invention provides a STATS inhibitor containing as an active ingredient, a quinolinecarboxamide derivative represented by the formula (I) (in the formula, W represents a bond or an alkylene chain; X represents O, S, or NR34; and R1 to R8 and R34 each represent H, halogen, alkyl, phenyl, furyl, thienyl, or the like), or a pharmacologically acceptable salt thereof.Type: GrantFiled: July 10, 2009Date of Patent: June 18, 2013Assignees: Pharma IP General Incorporated Association, Pharma Design, Inc., Shizuoka Prefecture, Kumamoto Health Science University, Kabushiki Kaisha Yakult HonshaInventors: Akira Asai, Kenji Matsuno, Naohisa Ogo, Takane Yokotagawa, Osamu Takahashi, Yasuto Akiyama, Tadashi Ashizawa, Tadashi Okawara
-
Publication number: 20120302524Abstract: Provided is a 1,3,4-oxadiazole-2-carboxamide compound which has STAT3 inhibitory activity and is useful as an anticancer agent. Provided is a 1,3,4-oxadiazole-2-carboxamide compound represented by formula (I) or a pharmacologically acceptable salt thereof (in the formula, Ar represents a furyl group or the like; R1 represents a hydrogen atom or the like; and —X—Y represents a diaryl group such as a biphenyl group).Type: ApplicationFiled: December 28, 2010Publication date: November 29, 2012Applicants: GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION, PHARMA DESIGN, INC., KABUSHIKI KAISHA YAKULT HONSHA, KUMAMOTO HEALTH SCIENCE UNIVERSITY, SHIZUOKA PREFECTUREInventors: Akira Asai, Kenji Matsuno, Naohisa Ogo, Osamu Takahashi, Yoshiaki Masuda, Ayumu Muroya, Yasuto Akiyama, Tadashi Ashizawa, Tadashi Okawara
-
Publication number: 20110172429Abstract: The present invention provides a STATS inhibitor containing as an active ingredient, a quinolinecarboxamide derivative represented by the formula (I) (in the formula, W represents a bond or an alkylene chain; X represents O, S, or NR34; and R1 to R8 and R34 each represent H, halogen, alkyl, phenyl, furyl, thienyl, or the like.), or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: July 10, 2009Publication date: July 14, 2011Applicants: PHARMA IP GENERAL INCORPORATED ASSOCIATION, PHARMA DESIGN, INC., SHIZUOKA PREFECTURE, KUMAMOTO HEALTH SCIENCE UNIVERSITY, KABUSHIKI KAISHA YAKULT HONSHAInventors: Akira Asai, Kenji Matsuno, Naohisa Ogo, Takane Yokotagawa, Osamu Takahashi, Yasuto Akiyama, Tadashi Ashizawa, Tadashi Okawara
-
Publication number: 20110091896Abstract: Disclosed are: a method for identifying/analyzing a gene for an antibody in one cell derived from a human; a technique for producing an antibody derived from an identified one B cell; and others. A gene for an antibody specific to a melanoma antigen is analyzed/identified at a one-cell level by using an immortalized B cell produced from peripheral blood monocytes from a melanoma patient or a primary B cell included in the peripheral blood monocytes. It is found that B cells capable of producing a specific antibody can be separated on one cell by one cell basis by staining the B cells with a GST-labeled melanoma-specific cancer antigen MAGE1, an Alexa-labeled anti-GST antibody and a PE-labeled anti-human IgG antibody and carrying out the single cell sorting of the stained B cells. Further, a practical technique for extracting total RNA from the separated one B cell and cloning a gene for a specific antibody into the total RNA efficiently can be established.Type: ApplicationFiled: June 4, 2009Publication date: April 21, 2011Applicant: SHIZUOKA PREFECTUREInventor: Yasuto Akiyama